Oncogenic and immunological targets for matched therapy of pediatric blood cancer patients: Dutch iTHER study experience

Oncogenic and immunological targets for matched therapy of pediatric blood cancer patients: Dutch iTHER study experience

Abstract Over the past 10 years, institutional and national molecular tumor boards have been implemented for relapsed or refractory pediatric cancer to prioritize targeted drugs for individualized treatment based on actionable oncogenic lesions, including the Dutch iTHER platform. Hematological mali...

Full description

Bibliographic Details
Main Authors: Judith M. Boer, Uri Ilan, Aurélie Boeree, Karin P. S. Langenberg, Jan Koster, Marco J. Koudijs, Jayne Y. Hehir‐Kwa, Stefan Nierkens, Corinne Rossi, Jan J. Molenaar, Bianca F. Goemans, Monique L. denBoer, C. Michel Zwaan
Format: Article
Language:English
Published: Wiley 2024-07-01
Series:HemaSphere
Online Access:https://doi.org/10.1002/hem3.122

Internet

https://doi.org/10.1002/hem3.122

Similar Items